The Department of Nutrition Sciences

Evaluation of a Medical Food for Chronic Wounds This study objective is to compare the outcomes in subjects with a diabetic foot ulcer after 16 weeks of consuming an argine, glutamine, B-hydroxy-B-methylburate containing medical versus a calorically similar low glycemic response control drink. Eligibility: Adults with type 1 or type 2 diabetes mellitus with a foot ulcer greater than 30 days, but not more than 12 months from 1cm to 10cm in size.

Purpose of this study is to examine the contributions of genetic and environmental factors on racial differences in the risk for diabetes.

HOPE study The purpose of this study is to investigate the effects of maternal weight status during pregnancy and of gestational diabetes on children’s obesity and diabetes risk. We seek healthy 5-10 year old Caucasian or African American children whose mothers had gestational diabetes during pregnancy. The study involves two visits for testing of the child, and the mother’s medical records from pregnancy with that child must be obtainable. Both mother and child will be compensated. If interested, please call Nikki or Paula at the HOPE study 934-0809

A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control MK-3577 is a glucagon receptor antagonist (GRA) and an investigational treatment for type 2 diabetes (T2DM). This study will assess the safety and efficacy of MK-3577 10-mg daily (taken in the morning), MK-3577 6-mg daily (taken in the evening) or MK-3577 50-mg daily (taken as 25-mg twice daily) compared to placebo. Eligibility: Patients, ages 19 to 70 years, with T2DM who are either not currently on an antihyperglycemic agent (AHA) with an A1C of 6.5% to 9.5%, or who are on AHA monotherapy or low-dose combination therapy [i.e., ¡Ü 50% maximum recommended dose (per label of the individual country) of each component] with an A1C of 6.0% to 9.0%, are eligible to participate.

A Randomized, Placebo Controlled Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination oral Antihyperglycemic Therapy The primary study objective is to compare the including sitagliptin as part of usual care versus usual care without sitagliptin (or other DPP-4 inhibitors or CLP-1 analogues) upon cardiovascular events. Phase 3 Eligibility: Adults over the age of 50 with type 2 diabetes receiving metformin, pioglitazone, or a sulfonylurea as monotherapy or in combination at least 3 months with a hemoglobin A1c of 6.5 or greater but equal to or less than 8.0 and a history of cardiovascular disease.

A Phase III, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303) to Detrmine the Safety and Efficacy of VI 0521 for the Long-term Treatment of Obesity in Adults with Obesity-Related Co-morbid Condition The purpose of this study is to evaluate the long-term efficacy and safety of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303. Phase 3 Eligibility: Completion of OB-303.